- Home
- Products
DABRAFENIB (Tafinlar)
DABRAFENIB (Tafinlar)
- Medicine Name: DABRAFENIB
- Generic Name: Tafinlar
- Dosage Form & Strength: 50 mg
- Form: Oral Capsules
- Manufactured By: GlaxoSmithKline
- FDA Approval Date: Yes (Approved on November 13, 2013)
DABRAFENIB (Tafinlar) is a BRAF kinase inhibitor used for treating cancers with the BRAF V600E mutation. It is often prescribed alone or in combination with Trametinib, a MEK inhibitor.
Approved Indications:
- Unresectable or metastatic melanoma with BRAF V600E mutation
- Adjuvant treatment of melanoma with BRAF V600E mutation after complete resection
- Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation (in combination with trametinib)
- Anaplastic thyroid cancer with BRAF V600E mutation (in combination with trametinib)
Click here to download full prescribing information.
Risk of fever, chills, and dehydration – monitor regularly
Cutaneous squamous cell carcinoma (cuSCC) and other skin malignancies may occur
Monitor for new primary malignancies
Risk of hyperglycemia, uveitis, and hemorrhage
Fetal harm may occur – contraception is advised during and after treatment
Use with caution in patients with renal or hepatic impairment
Required Documents to Import DABRAFENIB to India:
- Valid prescription from an oncologist
- Patient’s diagnostic reports showing BRAF mutation status
- Government-issued ID proof
- Import permit, if applicable under Indian law
Availability:
DABRAFENIB (Tafinlar 50 mg) is not commercially sold in Indian pharmacies but is available under the Named Patient Import Program. Available in major cities like Mumbai, Delhi, Bangalore, Chennai, Hyderabad, Pune, Ahmedabad, and others.
Global Rare Meds arranges legal import and sourcing of DABRAFENIB (Tafinlar 50 mg) from certified suppliers in the USA, Europe, Canada, and Australia.
Medications are verified and dispensed by licensed pharmacists
Dispatched from our Ambernath, Thane District fulfillment center
Delivered across India and globally, following compliance and documentation protocols
We ensure authenticity, transparency, and timely delivery.
What is the generic name of Tafinlar?
Dabrafenib
Who manufactures Dabrafenib?
GlaxoSmithKline
What is Dabrafenib used for?
It is used to treat certain cancers with BRAF V600E mutations, including melanoma, NSCLC, and anaplastic thyroid cancer.
What is the approved dosage form?
Oral Capsules – 50 mg (Also available in 75 mg in some markets)
Is Dabrafenib approved by the FDA?
Yes, Dabrafenib received FDA approval on November 13, 2013.
Is Dabrafenib available in India?
Not commercially, but it can be imported legally for personal use with valid documentation.
Is a generic version available?
No, there are currently no approved generics of Dabrafenib (Tafinlar).
How do I get Dabrafenib (Tafinlar) in India?
Contact Global Rare Meds with your prescription to initiate the import process.
What is the price of Tafinlar in India?
For accurate and up-to-date pricing:
Phone: +91-99675 15602
WhatsApp: +91-99675 15602
Email: info@globalraremeds.com
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
